Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy

Advanced melanoma is an aggressive skin cancer characterized by poor survival rates and response to cytotoxic chemotherapy. Immune checkpoint inhibitors are novel agents capable of utilizing one’s own immune system to bring about the tumor destruction. Nivolumab and pembrolizumab are fully humanized...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahni, Sakshi, Valecha, Gautam, Sahni, Ankit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372252/
https://www.ncbi.nlm.nih.gov/pubmed/30788189
http://dx.doi.org/10.7759/cureus.3700
_version_ 1783394708422131712
author Sahni, Sakshi
Valecha, Gautam
Sahni, Ankit
author_facet Sahni, Sakshi
Valecha, Gautam
Sahni, Ankit
author_sort Sahni, Sakshi
collection PubMed
description Advanced melanoma is an aggressive skin cancer characterized by poor survival rates and response to cytotoxic chemotherapy. Immune checkpoint inhibitors are novel agents capable of utilizing one’s own immune system to bring about the tumor destruction. Nivolumab and pembrolizumab are fully humanized anti-PD-1 monoclonal antibodies that have shown significant anti-tumor activity in a variety of cancers including melanoma and have significantly improved the survival outcomes in patients with advanced melanoma. In this updated review article, we will discuss the outcomes of various clinical trials evaluating the efficacy and safety of these agents. We will also briefly discuss their mechanism of action and adverse effects.
format Online
Article
Text
id pubmed-6372252
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-63722522019-02-20 Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy Sahni, Sakshi Valecha, Gautam Sahni, Ankit Cureus Dermatology Advanced melanoma is an aggressive skin cancer characterized by poor survival rates and response to cytotoxic chemotherapy. Immune checkpoint inhibitors are novel agents capable of utilizing one’s own immune system to bring about the tumor destruction. Nivolumab and pembrolizumab are fully humanized anti-PD-1 monoclonal antibodies that have shown significant anti-tumor activity in a variety of cancers including melanoma and have significantly improved the survival outcomes in patients with advanced melanoma. In this updated review article, we will discuss the outcomes of various clinical trials evaluating the efficacy and safety of these agents. We will also briefly discuss their mechanism of action and adverse effects. Cureus 2018-12-07 /pmc/articles/PMC6372252/ /pubmed/30788189 http://dx.doi.org/10.7759/cureus.3700 Text en Copyright © 2018, Sahni et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Sahni, Sakshi
Valecha, Gautam
Sahni, Ankit
Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
title Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
title_full Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
title_fullStr Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
title_full_unstemmed Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
title_short Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
title_sort role of anti-pd-1 antibodies in advanced melanoma: the era of immunotherapy
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372252/
https://www.ncbi.nlm.nih.gov/pubmed/30788189
http://dx.doi.org/10.7759/cureus.3700
work_keys_str_mv AT sahnisakshi roleofantipd1antibodiesinadvancedmelanomatheeraofimmunotherapy
AT valechagautam roleofantipd1antibodiesinadvancedmelanomatheeraofimmunotherapy
AT sahniankit roleofantipd1antibodiesinadvancedmelanomatheeraofimmunotherapy

Ejemplares similares